Yogev Debbi Debbi

Company: Mana Bio

Job title: Co-Founder & CEO

Bio:

Yogev Debbi is the Co-founder and CEO of Mana.bio, an AI-driven drug delivery company leveraging machine learning and high-throughput screening to develop tissue-specific lipid nanoparticle (LNP) delivery solutions. Under his leadership, Mana.bio has pioneered a data-driven approach to unlocking extrahepatic delivery of nucleic acid therapeutics. Prior to founding Mana.bio, Yogev co-founded Genome Compiler, a leading gene editing software platform that was acquired by Twist Bioscience (Nasdaq: TWST), a global leader in synthetic biology. Following the acquisition, he served as General Manager of Twist’s Israel R&D center, playing a key role in the company’s IPO. Yogev later held a senior leadership position at monday.com (Nasdaq: MNDY), contributing to its successful IPO and growth as a global enterprise software leader.

Seminars:

Designing Safer LNPs With Machine Learning: Reducing Immunogenicity & Toxicity Through Predictive Modeling 10:55 am

Discussing how machine learning models are being trained to predict innate immune activation, cytokine profiles, and complement responses based on LNP composition to optimize lipid and ligand selection early in the design process Using algorithm-driven screening to identify novel lipid structures with minimal immune stimulation and improved biocompatibility Applying machine learning to triage formulations prior…Read more

day: Conference Agenda

Q&A Session 11:50 am

Join our speakers for an interactive Q&A session, where they’ll come together to answer your questions, share further insights, and expand on key themes from their presentations.Read more

day: Conference Agenda